{"id":"W2413126406","doi":"","title":"Bortezomib (millennium pharmaceuticals).","year":2002,"lang":"en","type":"article","venue":"PubMed","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Bortezomib; Multiple myeloma; Medicine; Oncology; Proteasome inhibitor; Internal medicine; Clinical trial","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009908213,0.001616261,0.001033963,0.001775151,0.0006341215,0.001821076,0.001264529,0.00152242,0.1021642],"category_scores_gemma":[0.0009019352,0.0005468263,0.0006135303,0.0007125625,0.0003690142,0.001214223,0.001646692,0.002505631,0.07086356],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007861785,"about_ca_system_score_gemma":0.001341296,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004982611,"about_ca_topic_score_gemma":0.001180689,"domain_scores_codex":[0.999215,0.00007131811,0.00004546971,0.0001595556,0.0004102579,0.00009836239],"domain_scores_gemma":[0.9994681,0.00002587614,0.00007895938,0.00004105644,0.0001112965,0.0002746311],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001628439,0.0004267642,0.000715535,0.001763004,0.00009035832,0.0004533554,0.00005395841,0.0002408014,0.0550674,0.005584653,0.3177707,0.6162051],"study_design_scores_gemma":[0.0009680841,0.0006299659,0.001028795,0.0001570648,0.00004931713,0.001303752,0.00001028331,0.0001526975,0.01071091,0.001104186,0.983865,0.00001988681],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"other","genre_gemma":"other","genre_scores_codex":[0.02065466,0.2474695,0.01730146,0.01686464,0.006607182,0.001986809,0.02295158,0.01547645,0.6506877],"genre_scores_gemma":[0.1224906,0.1077632,0.04847921,0.01502302,0.001616974,0.001235032,0.0505478,0.001080038,0.6517642],"genre_candidate":"other","genre_consensus":"other","teacher_disagreement_score":0.1021642,"threshold_uncertainty_score":0.3417734,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1138465950922523,"score_gpt":0.3206849202111406,"score_spread":0.2068383251188883,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}